OncoMatch/Clinical Trials/NCT06437496

68Ga-AAZTA-093 PET/CT: First-in-human Study

Is NCT06437496 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including 68Ga-AAZTA-093 and 68Ga-PSMA-11//68Ga-PSMA-617 for malignant neoplasm of prostate.

Early Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT06437496Data as of May 2026

Treatment: 68Ga-AAZTA-093 · 68Ga-PSMA-11//68Ga-PSMA-617 — 68Ga-AAZTA-093 is a novel radiotracer targeting prostate-specific membrane antigen (PSMA). In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-093 PET/CT in patients with prostate cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify